Literature DB >> 20673799

Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions.

Jack van Horssen1, Joost A R Drexhage, Thomas Flor, Wouter Gerritsen, Paul van der Valk, Helga E de Vries.   

Abstract

Oxidative stress plays a major role in multiple sclerosis (MS), a chronic inflammatory central nervous system (CNS) disease. Invading leukocytes contribute to cell damage and demyelination by producing excessive amounts of cytotoxic mediators, including reactive oxygen species (ROS). To counteract the damaging effects of ROS the CNS is endowed with a repertoire of endogenous antioxidant enzymes, which are regulated by the transcription factor NF-E2-related factor 2 (Nrf2). Upon exposure to ROS, Nrf2 translocates to the nucleus allowing transcriptional activation of various antioxidant enzymes. DJ1 is a protein that is involved in the stabilization of Nrf2 and hence acts as a positive regulator of Nrf2-driven antioxidant protection. Here, we investigate the (sub)cellular localization of Nrf2 and DJ1 in various MS lesion stages and show that Nrf2 is strikingly upregulated in active MS lesions, in both the nucleus and the cytoplasm of infiltrating macrophages and to a lesser extent in reactive astrocytes. Simultaneously, DJ1 protein expression is predominantly increased in astrocytes in both active and chronic inactive MS lesions compared to control brain tissue and normal-appearing white matter. Together, our findings suggest that persistent Nrf2-mediated transcription occurs in active MS lesions, but that this endogenous response is insufficient to prevent ROS-induced cellular damage, which is abundant in inflammatory MS lesions.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673799     DOI: 10.1016/j.freeradbiomed.2010.07.013

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  44 in total

Review 1.  Redox-based therapeutics in neurodegenerative disease.

Authors:  G J McBean; M G López; F K Wallner
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

Review 2.  Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection.

Authors:  Meijuan Zhang; Chengrui An; Yanqin Gao; Rehana K Leak; Jun Chen; Feng Zhang
Journal:  Prog Neurobiol       Date:  2012-09-29       Impact factor: 11.685

Review 3.  Role of nrf2 in oxidative stress and toxicity.

Authors:  Qiang Ma
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

4.  Response to oxidative stress of peripheral blood mononuclear cells from multiple sclerosis patients and healthy controls.

Authors:  Cristiana Pistono; Maria Cristina Monti; Chiara Boiocchi; Francesca Gigli Berzolari; Cecilia Osera; Giulia Mallucci; Mariaclara Cuccia; Alessia Pascale; Cristina Montomoli; Roberto Bergamaschi
Journal:  Cell Stress Chaperones       Date:  2019-11-12       Impact factor: 3.667

5.  Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls.

Authors:  Dorothee Nickles; Hsuan P Chen; Michael M Li; Pouya Khankhanian; Lohith Madireddy; Stacy J Caillier; Adam Santaniello; Bruce A C Cree; Daniel Pelletier; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini
Journal:  Hum Mol Genet       Date:  2013-06-06       Impact factor: 6.150

Review 6.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

Review 7.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 8.  Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.

Authors:  Ralf A Linker; Ralf Gold
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

Review 9.  BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors.

Authors:  Nirmalya Chatterjee; Dirk Bohmann
Journal:  Bioessays       Date:  2018-03-30       Impact factor: 4.345

Review 10.  The role of inflammation in sporadic and familial Parkinson's disease.

Authors:  Michela Deleidi; Thomas Gasser
Journal:  Cell Mol Life Sci       Date:  2013-05-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.